Launch of IDS-iSYS ACTH assay

Immunodiagnostic Systems Holdings plc.

2 February 2016

Launch of IDS-iSYS ACTH assay - new assay in the IDS hypertension portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, today launched the IDS-iSYS ACTH assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The IDS-iSYS ACTH assay will become a key assay within the existing IDS portfolio for endocrine hypertension testing.

The IDS-iSYS ACTH assay measures a patient's levels of adrenocorticotropic hormone to allow the assessment of pituitary and adrenal gland function. Together with other clinical and laboratory data it allows the differential diagnosis of hyper- and hypo-cortisolism disorders such as Cushing's syndrome and Addison's disease, as well as the evaluation of other causes of endocrine hypertension.

The Global market size of ACTH testing is estimated to be approximately £10-15 million.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson